Middle meningeal artery embolization for subdural hematoma: protocol for a systematic review and meta-analysis of randomized

3 controlled trials

- 4 Alick P Wang^{*1} MD MSc, Husain Shakil² MD MSc, Brian J Drake¹ MBBCh MPH FRCSC
- 5 1. Division of Neurosurgery, Department of Surgery, University of Ottawa
- 6 2. Division of Neurosurgery, Department of Surgery, University of Toronto
- 7 * Corresponding author:
- 8 Alick P Wang, MD MSc
- 9 The Ottawa Hospital, Civic Campus
- 10 1053 Carling Ave, Ottawa Ontario, Canada, K1Y4E9
- 11 alickwang@gmail.com

12 Abstract

- 13 (178 words)
- 14 Background: Middle meningeal artery embolization is an emerging neuroendovascular therapy
- 15 for chronic subdural hematoma. Recently, a number of randomized control trials have been
- 16 conducted to assess the efficacy of middle meningeal artery embolization to reduce the
- 17 recurrence or progression of chronic subdural hematoma.
- 18 Methods: A systematic review will be conducted following the Preferred Reporting Items for
- 19 Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The authors will systematically
- 20 search MEDLINE, EMBASE, Cochrane, and ClinicalTrials.gov (National Library of Medicine)
- 21 for randomized control trials evaluating middle meningeal artery embolization for chronic
- subdural hematoma. A meta-analysis will be undertaken to compare patients undergoing middle
- 23 meningeal artery embolization and standard care compared to standard care alone; primary
- 24 effectiveness endpoints will be symptomatic recurrence, radiographic re-accumulation, or
- 25 reoperation; secondary safety endpoints will be new disabling stroke, myocardial infarction, or
- 26 death within 30 days.
- 27 Discussion: This proposed systematic review and meta-analysis will synthesize and appraise
- 28 available data regarding middle meningeal artery embolization, a novel neurointerventional
- 29 therapy. Findings will help clinicians, patients, administrators, policy makers to determine the
- 30 role of this new treatment and its potential benefits.
- 31 Systematic review registration: PROSPERO #CRD42024512049

32 Keywords

33 Meta-analysis; Middle meningeal artery embolization; Randomized control trial; Subdural

34 hematoma.

35 Background

- 36 Chronic subdural hematoma (CSDH) is a common condition, with an incidence of up to 20.6 per
- 37 100,000 person-years¹. It disproportionately affects elderly populations and is often caused by
- 38 minor trauma. It can cause symptoms ranging from headaches to confusion, decreased level of
- 39 consciousness, weakness, aphasia, or seizures.
- 40 Depending on the volume, local mass effect, and symptoms, chronic SDH has been treated either
- 41 surgically (burr hole evacuation, craniotomy, or subdural drainage ports) or conservatively
- 42 (medical therapy or observation/serial imaging). Conservatively managed SDH can progress in
- 43 up to 34% of cases². After surgical evacuation, recurrence rates have been estimated between 10-
- 44 $20\%^3$.
- 45 Recently, endovascular embolization of the middle meningeal artery (EMMA) has become an
- 46 emerging therapy for $CSDH^4$. While EMMA was initially used in patients who were at high risk
- 47 of recurrence, the indications have recently widened to all patients with CSDH. Although
- 48 EMMA does not immediately remove the SDH or its mass effect, it is hypothesized to
- 49 devascularize the subdural membrane and prevent recurrence or progression.
- 50 EMMA has been used in cases of small, asymptomatic SDH not requiring surgery⁵ as well as in
- 51 cases of SDH requiring surgical evacuation⁶. A recent systematic review found that EMMA
- reduced the risk of recurrence from 23.5% to 3.5% $(RR \ 0.17)^7$. However, at the time of
- 53 publication, there had not been any prospectively conducted randomized control trials (RCTs).
- 54 Recently, a number of multi-centre RCTs have been conducted to evaluate the efficacy of
- 55 EMMA for reducing recurrence or progression in CSDH. A meta-analysis of these trials has yet
- to be performed.

57 Methods/Design

- 58 This protocol outlines the design and conduct of our intended systematic review and meta-
- 59 analysis in compliance with the guideline Preferred Reporting Items for Systematic Reviews and
- 60 Meta-analyses (PRISMA). The protocol has been submitted to the PROSPERO database and
- 61 assigned the unique identifier #CRD42024512049. This study was exempt from institutional
- 62 research ethics board review under article 1B of the University of Toronto policy on Human
- 63 Research Exempt from REB Review (https://research.utoronto.ca/ethics-human-
- 64 research/activities-exempt-human-ethics-review)

65 Study Aim

- 66 We aim to conduct a meta-analysis of available data from RCTs comparing the efficacy of
- 67 EMMA in addition to standard of care to standard of care alone. The primary efficacy endpoints
- 68 will be the likelihood of SDH recurrence, re-accumulation, or re-operation at 90 days, and 180
- 69 days.

70 Data Sources and Study Eligibility

- 71 Two authors (APW, HS) will independently search citations from MEDLINE, EMBASE,
- 72 Cochrane, and ClinicalTrials.gov (National Library of Medicine) without language restriction
- 73 (see Appendix 1 for search strategy). We will include randomized control trials studying adult
- patients (\geq 18 years of age) with radiographic diagnosis of chronic or subacute SDH, with at
- r5 least 10 patients, and at least 90 days of follow-up.

76 Treatment Groups

- 77 The intervention group of interest will be the use of EMMA in addition to standard of care. The
- control group will be treatment with standard of care alone. Standard of care will include
- 79 observation, medical therapy, burr hole, mini-craniotomy, craniotomy, and subdural evacuation
- 80 port system.

81 *Outcomes*

- 82 The primary effectiveness endpoints for this study will be symptomatic recurrence, radiographic
- re-accumulation, or reoperation at 90, and 180 days. We will also aim to assess a secondary
- 84 safety endpoint of new major disabling stroke, myocardial infarction, or death from any
- 85 neurological cause within 30 days.

86 Data Extraction

- 87 Spreadsheet software will be used by two authors (APW, HS) to extract study design,
- 88 inclusion/exclusion criteria, randomization characteristics, patient population, primary and
- 89 secondary outcome measures, and sources of bias, and covariates. Covariates will include age,
- 90 standard treatment approach used, presence of symptoms, type of embolization material, and use
- 91 of general anesthetic for EMMA procedure.

92 Risk of Bias/Quality Assessment

- 93 Two reviewers (APW, HS) will independently perform quality assessment of included studies.
- The Cochrane ROB 2 tool⁸ will be applied to assess the risk of bias related to the randomization 94
- process, deviations from intended interventions, missing data, measurement of the outcome, and 95
- 96 selection of the reported results. We judged trials with more than 2 high-risk components as
- having a moderate overall risk of bias, and trials with more than 4 high-risk components as 97
- having a high overall risk of bias. The GRADE approach⁹ will be used for appraisal of the 98
- 99 quality of evidence.

100 Statistical Analysis

- All analyses will be conducted in R version 4.3.1 with a priori specified significance level of p < p101
- 102 0.05 for two-tailed tests. We will follow an intention-to-treat approach in assigning treatment 103 groups.
- 104 The odds ratio (OR) of SDH recurrence and associated 95% confidence intervals (CI) for
- 105 EMMA with standard therapy compared to standard therapy alone will be estimated for each 106 study using logistic regression.
- Heterogeneity in the treatment effect across trials will be investigated by the Cochran Q test and 107
- measured by the I^2 statistic, with I^2 values exceeding 25%, 50%, and 75% representing low, 108
- moderate, and high heterogeneity, respectively¹⁰. Treatment effect estimates will be pooled using 109
- a fixed effect Mantel-Haenszel method if heterogeneity is found to be low heterogeneity. A 110
- DerSimonian and Laird random-effects model¹¹ will be used if moderate-high heterogeneity is 111 112 found.
- Publication bias will be assessed using Funnel plots and Egger's test¹². We will further 113
- 114 investigate the effect of covariates including age, standard treatment approach, presence of
- 115 symptoms, history of prior subdural hematoma, use of general anesthetic, and type of
- embolization material used. We will assess missingness of covariates and outcomes. Based on 116
- 117 data availability, we will conduct subgroup analyses based on presence of symptoms, type of
- 118 standard management (e.g. conservative, medical, burr-hole, and craniotomy), older patients, or 119 patients with prior subdural hematoma. We will not impute data on outcomes or treatment
- 120 assignment, and will only analyze available data for these variables. For study covariates, we
- 121 will impute data found to be missing completely at random, or missing at random there is less
- 122 than 20% missingness.

123 Discussion

- 124 This proposed systematic review and meta-analysis will address an important knowledge gap
- 125 regarding EMMA, a novel neurointerventional therapy.
- 126 While several studies have evaluated the safety and benefit of EMMA³, up until recently there
- had not been any prospective RCTs conducted to evaluate its efficacy. Recently, a number of
- 128 multi-centre RCTs have been completed and early results have been presented at the
- 129 International Stroke Conference 2024.
- 130 A meta-analysis of RCTs will help clinicians, patients, administrators, policy makers to
- 131 determine the role of this new treatment and its potential benefits.

132 List of abbreviations

- 133 CSDH chronic subdural hematoma
- 134 EMMA embolization of the middle meningeal artery
- 135 MMA middle meningeal artery
- 136 PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses
- 137 RCT randomized control trial
- 138 SDH subdural hematoma

139 **Declarations**

- 140 Ethics approval
- 141 No ethics approval required for systematic review.
- 142 Availability of data and materials
- All data will be extracted from publicly available publications. Extracted data will be madeavailable upon reasonable request.
- 145 Competing interests
- 146 No competing interests to declare.
- 147 Funding
- 148 No funding to declare.
- 149 Authors' contributions
- 150 APW, HS, and BJD study conception. APW and HS protocol design and drafting.

151 **References**

- Feghali, J., Yang, W. & Huang, J. Updates in Chronic Subdural Hematoma: Epidemiology, Etiology, Pathogenesis, Treatment, and Outcome. World Neurosurg 141, 339–345 (2020).
- Foppen, M., Bandral, H. V., Slot, K.-A. M., Vandertop, W. P. & Verbaan, D. Success of conservative therapy for chronic subdural hematoma patients: a systematic review.
 Frontiers in Neurology 14, (2023).
- Almenawer, S. A. et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg 259, 449–457 (2014).
- 4. Rudy, R. F., Catapano, J. S., Jadhav, A. P., Albuquerque, F. C. & Ducruet, A. F. Middle
 Meningeal Artery Embolization to Treat Chronic Subdural Hematoma. Stroke: Vascular
 and Interventional Neurology 3, e000490 (2023).
- 162 5. Rojas-Villabona, A. et al. A systematic review of middle meningeal artery embolization for minimally symptomatic chronic subdural haematomas that do not require immediate
 164 evacuation. Brain and Spine 3, 102672 (2023).
- 165 6. Lam, A. et al. The efficacy of postoperative middle meningeal artery embolization on
 166 chronic subdural hematoma A multicentered randomized controlled trial. Surg Neurol Int
 167 14, 168 (2023).
- 168 7. Dian, J., Linton, J. & Shankar, J. J. Risk of recurrence of subdural hematoma after EMMA
 169 vs surgical drainage Systematic review and meta-analysis. Interv Neuroradiol 27, 577–
 170 583 (2021).
- 171 8. Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.
 172 BMJ 366, 14898 (2019).
- 9. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924–926 (2008).
- 175 10. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency
 176 in meta-analyses. BMJ 327, 557–560 (2003).
- 177 11. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177–
 178 188 (1986).
- 179 12. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by
 a simple, graphical test. BMJ 315, 629–634 (1997).

Appendix 1: 181

182 Search Strategy

- The following search strategy will be employed for the MEDLINE database using the OVID 183 184
- interface.
- 1. exp Hematoma, Subdural/ 185
- 186 2. exp Embolization Therapeutic/
- 3. exp Meningeal Arteries/ 187
- 4. exp Endovascular Procedures/ 188
- 5. Exp Clinical Trial/ 189
- 6. 2 or 3 or 4 190
- 191 7. 1 and 5 and 6